{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-034618","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.030238+00:00","generated_at":"2026-05-16T20:25:43.900619+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Monopar Therapeutics Q3 2025 net loss $3.4M; cash $143.7M; NDA for ALXN1840 planned early 2026","bullets":["Net loss $3.4M ($0.48/sh) vs $1.3M ($0.37/sh) in Q3 2024; no revenue reported.","Cash, equivalents & investments $143.7M as of Sep 30, 2025; funds expected through Dec 2027.","NDA submission to FDA for ALXN1840 in Wilson disease targeted for early 2026.","Raised ~$126.9M gross in public offering; $35M used to repurchase 550,229 shares from Tactic Pharma, net ~$91.9M.","FDA cleared IND for MNPR-101-Lu therapeutic radiopharmaceutical trial in solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-034618","json":"https://secwatch.observer/filing/0001437749-25-034618.json","markdown":"https://secwatch.observer/filing/0001437749-25-034618.md","text":"https://secwatch.observer/filing/0001437749-25-034618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925034618/0001437749-25-034618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925034618/mnpr20251105_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:25:43.900619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}